ItalianoGUARNERI, Valentina
Pubblicazioni
Risultati 1 - 20 di 133 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer | 2017 | Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V |
| 2 | 35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS | 2010 | Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V. |
| 3 | 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio | 2018 | Conte, P. F.; Guarneri, V.; Bisagni, G.; Piacentini, F.; Brandes, A. A.; Cavanna, L.; Giotta, F.; Aieta, M.; Gebbia, V.; Frassoldati, A.; Musolino, A.; Garrone, O.; Taverniti, C.; Rimanti, A.; Sarti, S.; Rubino, D.; Bologna, A.; Vicini, R.; Balduzzi, S.; D'Amico, R. |
| 4 | 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. | 2018 | Conte, P; Frassoldati, A; Bisagni, G; Brandes, Aa; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, Ea; Vicini, R; Balduzzi, Sara; D'Amico, R; Guarneri, Valentina |
| 5 | 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. | 2010 | Guarneri, Valentina; Frassoldati, A; Gebbia, V; Bisagni, G; Cavanna, L; Donadio, M; Lelli, G; Musolino, A; Colucci, G; Banna, Gl; Degli Esposti, R; Ferro, A; Grasso, F; Zamagni, C; Amadori, D; Aieta, M; Molino, A; Garrone, O; Aitini, E; Fornari, G; Cascinu, Stefano; Rossi, G; D'Amico, Roberto; Conte, Pierfranco |
| 6 | A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy | 2008 | Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco |
| 7 | A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. | 2009 | Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco |
| 8 | Achievements and unmet needs in the management of advanced ovarian cancer | 2010 | Guarneri, Valentina; Piacentini, Federico; Barbieri, Elena; Conte, Pierfranco |
| 9 | ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER | 2010 | Conte, P.; Piacentini, F.; Barbieri, E.; Guarneri, V. |
| 10 | Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy | 2004 | A., Gennari; P., Bruzzi; C., Orlandini; B., Salvadori; S., Donati; E., Landucci; Guarneri, Valentina; M., Rondini; S., Ricci; Conte, Pierfranco |
| 11 | Acute and subacute toxicities of medical anticancer treatment. ESMO handbook of cancer diagnosis and treatment evaluation, pag 79-99 . Informa Healthcare USA, 2009, ISBN 978-1-841-84703-0 | 2009 | Guarneri, Valentina; Conte, Pierfranco |
| 12 | Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials | 2009 | Guarneri, Valentina; Miles, D; Robert, Nj; Dieras, Vc; Glaspy, J; Smith, Ie; Thomssen, C; Biganzoli, L; Taran, T; Conte, Pierfranco |
| 13 | Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. | 2009 | Guarneri, Valentina; A., Frassoldati; A., Bottini; K., Cagossi; L., Cavanna; A., Ravaioli; D., Amadori; G., Giardina; C., Oliva; Conte, Pierfranco |
| 14 | Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer | 2010 | Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco |
| 15 | Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. | 2019 | Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V. |
| 16 | Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. | 2010 | Guarneri, Valentina; Miles, D; Robert, N; Diéras, V; Glaspy, J; Smith, I; Thomssen, C; Biganzolil, ; Taran, T; Conte, Pierfranco |
| 17 | Bevacizumab treatment for advanced breast cancer. | 2011 | Alvarez, Rh; Guarneri, Valentina; Icli, F; Johnston, S; Khayat, D; Loibl, S; Martin, M; Zielinski, C; Conte, Pierfranco; Hortobagyi, Gn |
| 18 | Biomarker expression and survival after primary chemotherapy for breast cancer. | 2006 | Guarneri, Valentina; Piacentini, Federico; Jovic, Gordana; Frassoldati, A; Ficarra, G; Giovannelli, Simona; Maur, M; Borghi, F; Vicini, Roberto; Conte, Pierfranco |
| 19 | Biomarkers predicting clinical benefit: fact or fiction? | 2011 | Guarneri, Valentina; Barbieri, Elena; Conte, Pierfranco |
| 20 | Bisphosphonates | 2008 | Guarneri, Valentina |
Dettaglio
GUARNERI, Valentina
Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto
Copyright © 2020